'Remarkable' drug reduces Alzheimer's decline, study shows | Health News
Experts say trial provides more evidence that targeting plaque proteins in brain can slow the disease’s progression.
Stay updated with breaking news from Mark Mintun. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Experts say trial provides more evidence that targeting plaque proteins in brain can slow the disease’s progression.
More than half of patients with Alzheimer disease administered donanemab showed a significantly reduced cognitive and functional decline.
'Remarkable' Alzheimer's drug reduces cognitive decline, study shows
The second such drug in a year raises hopes we can start treating dementia.
The success means patients and their caregivers could soon have another therapy shown to slow the disease alongside Leqembi — made by Cambridge biotech Biogen and Japanese drug maker Eisai — which was approved in January.